Category - Developments

Appili Therapeutics

Appili to receive funding for new antibiotic

Closely-held Appili Therapeutics will be receiving an additional $400,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to support development of ATI-1503, an antibiotic...


BioTime forms new AgeX unit on human aging

BioTime (NYSE MKT:BTX) has created AgeX Therapeutics, which will consolidate certain BioTime subsidiaries and programs in the field of interventional gerontology. The formation of AgeX continues the implementation of...

Jaguar Animal Health

Jaguar, Napo update commercial activities

Jaguar Animal Health (NASDAQ:JAGX) and closely-held Napo Pharmaceuticals, which are in the process of merging, updated their commercial activities. Jaguar is launching a national TV advertising campaign this month for...

RepliCel Life Sciences

RepliCel posts positive RCS-01 interim results

RepliCel Life Sciences (OTCQB:REPCF; TSXV:RP; FRA:P6P2) reported statistically and clinically significant positive data from an interim analysis of its Phase I study evaluating RCS-01 for the treatment of aging and sun...

IntelGenx Logo

IntelGenx, Tetra to develop Dronabinol XL tablet

IntelGenx (OTCQX:IGXT; TSXV:IGX) and Tetra Bio-Pharma (CSE:TBP; OTC:GRPOF) signed a definitive agreement to develop and commercialize a drug product containing the cannabinoid, Dronabinol, for the management of anorexia...

Jaguar Animal Health

Jaguar, Napo in definitive merger accord

Jaguar Animal Health (NASDAQ:JAGX) and closely-held Napo Pharmaceuticals have entered into a definitive merger agreement by unanimous approval by the boards of both companies. Under the accord, Jaguar’s stockholders and...

3D Signatures

3DS completes assay validation for HL

3D Signatures (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) has successfully completed internal analytical assay validation for its Hodgkin’s lymphoma (HL) test (Telo-HL) according to FDA guidelines. Assay validation of Telo...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.